CANF
Can-fite Biopharma·AMEX
--
--(--)
--
--(--)
CANF fundamentals
During FY 2025, Can-fite Biopharma (CANF) reported revenue of 405.00K, a YoY change of -39.91%. Net income was -9.83M, a YoY change of -24.72%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2015 | FY,2016 | H1,2017 | FY,2017 | Q1,2018 | H1,2018 | FY,2018 | Q1,2019 | FY,2019 | Q1,2020 | H1,2020 | 9M,2020 | FY,2020 | Q1,2021 | H1,2021 | 9M,2021 | FY,2021 | Q1,2022 | H1,2022 | 9M,2022 | FY,2022 | Q1,2023 | H1,2023 | 9M,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | TTM |
|---|
Start Date | Jan 1, 2015 | Jan 1, 2016 | Jan 1, 2017 | Jan 1, 2017 | Jan 1, 2018 | Jan 1, 2018 | Jan 1, 2018 | Jan 1, 2019 | Jan 1, 2019 | Jan 1, 2020 | Jan 1, 2020 | Jan 1, 2020 | Jan 1, 2020 | Jan 1, 2021 | Jan 1, 2021 | Jan 1, 2021 | Jan 1, 2021 | Jan 1, 2022 | Jan 1, 2022 | Jan 1, 2022 | Jan 1, 2022 | Jan 1, 2023 | Jan 1, 2023 | Jan 1, 2023 | Jan 1, 2023 | Jan 1, 2024 | Jan 1, 2024 | Jan 1, 2025 | Jan 1, 2025 | -- |
End Date | Dec 31, 2015 | Dec 31, 2016 | Jun 30, 2017 | Dec 31, 2017 | Mar 31, 2018 | Jun 30, 2018 | Dec 31, 2018 | Mar 31, 2019 | Dec 31, 2019 | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Jun 30, 2024 | Dec 31, 2024 | Jun 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 164.79K -- | 165.00K +0.13% | 136.00K -- | 789.00K +378.18% | 632.00K -- | 902.00K +563.24% | 3.82M +384.16% | 299.00K -52.69% | 2.03M -46.81% | 198.00K -33.78% | 402.00K -- | 613.00K -- | 763.00K -62.45% | 148.00K -25.25% | 398.00K -1.00% | 649.00K +5.87% | 853.00K +11.80% | 205.00K +38.51% | 409.00K +2.76% | 613.00K -5.55% | 810.00K -5.04% | 196.00K -4.39% | 392.00K -4.16% | 588.00K -4.08% | 743.00K -8.27% | 316.00K -19.39% | 674.00K -9.29% | 202.00K -36.08% | 405.00K -39.91% | 405.00K -- |
Sales and Services Revenue | 164.79K -- | 165.00K +0.13% | 136.00K -- | 789.00K +378.18% | 632.00K -- | 902.00K +563.24% | 3.82M +384.16% | 299.00K -52.69% | 2.03M -46.81% | 198.00K -33.78% | 402.00K -- | 613.00K -- | 763.00K -62.45% | 148.00K -25.25% | 398.00K -1.00% | 649.00K +5.87% | 853.00K +11.80% | 205.00K +38.51% | 409.00K +2.76% | 613.00K -5.55% | 810.00K -5.04% | 196.00K -4.39% | 392.00K -4.16% | 588.00K -4.08% | 743.00K -8.27% | 316.00K -19.39% | 674.00K -9.29% | 202.00K -36.08% | 405.00K -39.91% | 405.00K -- |
Gross Profit | 164.79K -- | 165.00K +0.13% | 136.00K -- | 789.00K +378.18% | 632.00K -- | 902.00K +563.24% | 3.82M +384.16% | 299.00K -52.69% | -- -- | 198.00K -33.78% | 402.00K -- | 613.00K -- | -- -- | 148.00K -25.25% | 398.00K -1.00% | 649.00K +5.87% | -- -- | 205.00K +38.51% | 409.00K +2.76% | 613.00K -5.55% | -- -- | 196.00K -4.39% | -- -- | 588.00K -4.08% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 6.58M -- | 8.85M +34.42% | 3.81M -- | 7.97M -9.88% | 2.22M -- | 4.46M +17.01% | 9.23M +15.80% | 2.01M -9.46% | 14.04M +52.04% | 4.47M +122.59% | 8.51M -- | 11.20M -- | 14.90M +6.15% | 2.32M -48.17% | 5.70M -32.99% | 9.46M -15.50% | 13.70M -8.10% | 2.58M +11.04% | 4.85M -14.96% | 7.63M -19.41% | 10.91M -20.37% | 2.91M +12.93% | 4.89M +0.80% | 6.95M -8.88% | 8.94M -18.05% | 4.41M -9.78% | 8.80M -1.50% | 5.10M +15.65% | 10.36M +17.62% | 10.36M -- |
Selling, General and Administrative Expenses | 2.73M -- | 2.73M +0.29% | 1.37M -- | 2.87M +4.94% | 907.00K -- | 1.82M +32.48% | 3.16M +10.15% | 567.00K -37.49% | 3.06M -3.04% | 703.00K +23.99% | 1.46M -- | 2.14M -- | 2.95M -3.66% | 1.02M +44.52% | 1.89M +30.03% | 2.71M +26.59% | 3.85M +30.29% | 754.00K -25.79% | 1.58M -16.70% | 2.32M -14.63% | 3.14M -18.26% | 847.00K +12.33% | 1.47M -6.66% | 2.23M -3.63% | 2.96M -5.98% | 1.52M +3.67% | 3.05M +3.11% | 2.07M +35.48% | 3.66M +20.18% | 3.66M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 3.06M -- | -- -- | -- -- | -- -- | 2.95M -3.66% | -- -- | -- -- | -- -- | 3.85M +30.29% | -- -- | -- -- | -- -- | 3.14M -18.26% | -- -- | 1.47M -- | -- -- | 2.96M -5.98% | 1.52M +3.67% | 3.05M +3.11% | 2.07M +35.48% | 3.66M +20.18% | 3.66M -- |
Research and Development Expenses | 3.86M -- | 6.12M +58.52% | 2.44M -- | 5.11M -16.50% | 1.31M -- | 2.64M +8.29% | 6.08M +18.98% | 1.44M +9.90% | 10.98M +80.67% | 3.77M +161.33% | 7.05M -- | 9.05M -- | 11.95M +8.88% | 1.30M -65.45% | 3.81M -45.99% | 6.75M -25.47% | 9.85M -17.58% | 1.82M +39.75% | 3.27M -14.09% | 5.31M -21.34% | 7.76M -21.19% | 2.06M +13.18% | 3.42M +4.40% | 4.72M -11.17% | 5.98M -22.93% | 2.88M -15.57% | 5.76M -3.78% | 3.03M +5.16% | 6.69M +16.26% | 6.69M -- |
Operating Income | -6.42M -- | -8.68M -35.30% | -3.67M -- | -7.18M +17.25% | -1.59M -- | -3.56M +3.21% | -5.41M +24.65% | -1.71M -7.75% | -12.01M -121.78% | -4.28M -149.91% | -8.11M -- | -10.59M -- | -14.14M -17.76% | -2.17M +49.23% | -5.30M +34.58% | -8.81M +16.74% | -12.84M +9.17% | -2.37M -9.17% | -4.44M +16.29% | -7.01M +20.43% | -10.10M +21.38% | -2.71M -14.43% | -4.50M -1.26% | -6.36M +9.30% | -8.20M +18.83% | -4.09M +8.94% | -8.13M +0.79% | -4.90M -19.64% | -9.95M -22.39% | -9.95M -- |
Non-Operating Income (Loss) | 1.36M -- | 319.00K -76.47% | 158.00K -- | 781.00K +144.83% | -133.00K -- | 590.00K +273.42% | -1.15M -247.63% | -121.00K +9.02% | -618.00K +46.40% | -66.00K +45.45% | -128.00K -- | -224.00K -- | -304.00K +50.81% | 293.00K +543.94% | 207.00K +261.72% | 317.00K +241.52% | 227.00K +174.67% | -64.00K -121.84% | -185.00K -189.37% | -141.00K -144.48% | -77.00K -133.92% | 162.00K +353.13% | 276.00K +249.19% | 379.00K +368.79% | 561.00K +828.57% | 137.00K -50.36% | 250.00K -55.44% | 22.00K -83.94% | 122.00K -51.20% | 122.00K -- |
Gain (Loss) on Other Investment | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 11.00K -- | -- -- | -14.00K -227.27% | -- -- | -4.00K +71.43% | -4.00K -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 58.00K -- | -- -- | -13.00K -122.41% | -- -- | -144.00K -1007.69% | -144.00K -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | 769.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -14.00K -- | -- -- | -14.00K -- | -- -- | -14.00K -- | -14.00K -- |
Net Interest Expense | -1.36M -- | -319.00K +76.47% | -158.00K -- | -12.00K +96.24% | 133.00K -- | -590.00K -273.42% | 1.15M +9708.33% | 121.00K -9.02% | 618.00K -46.40% | 66.00K -45.45% | 128.00K -- | 224.00K -- | 304.00K -50.81% | -293.00K -543.94% | -207.00K -261.72% | -317.00K -241.52% | -227.00K -174.67% | 64.00K +121.84% | 185.00K +189.37% | 141.00K +144.48% | 77.00K +133.92% | -162.00K -353.13% | -276.00K -249.19% | -379.00K -368.79% | -506.00K -757.14% | -137.00K +50.36% | -291.00K +42.49% | -22.00K +83.94% | -284.00K +2.41% | -284.00K -- |
Interest Expense | 564.58K -- | 55.00K -90.26% | 305.00K -- | 621.00K +1029.09% | 139.00K -- | 346.00K +13.44% | -- -- | 130.00K -6.47% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Income | 1.92M -- | 374.00K -80.52% | 463.00K -- | 633.00K +69.25% | 6.00K -- | 936.00K +102.16% | -- -- | 9.00K +50.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 276.00K -- | -- -- | 506.00K -- | 137.00K -50.36% | 291.00K -42.49% | 22.00K -83.94% | 284.00K -2.41% | 284.00K -- |
Pretax Income From Continuing Operations | -5.06M -- | -8.36M -65.22% | -3.52M -- | -6.40M +23.43% | -1.72M -- | -2.96M +15.65% | -6.57M -2.55% | -1.83M -6.45% | -12.63M -92.25% | -4.34M -137.01% | -8.23M -- | -10.81M -- | -14.44M -14.40% | -1.88M +56.75% | -5.10M +38.11% | -8.50M +21.40% | -12.62M +12.66% | -2.43M -29.61% | -4.63M +9.26% | -7.15M +15.81% | -10.17M +19.36% | -2.55M -4.77% | -4.22M +8.76% | -5.98M +16.38% | -7.63M +24.96% | -3.96M +6.23% | -7.88M -3.22% | -4.88M -23.22% | -9.83M -24.72% | -9.83M -- |
Income Tax Expense | 4.36K -- | 29.00K +565.64% | -- -- | 29.00K -- | -- -- | -- -- | 4.00K -86.21% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -5.07M -- | -8.39M -65.65% | -3.52M -- | -6.43M +23.35% | -1.72M -- | -2.96M +15.65% | -6.57M -2.15% | -1.83M -6.45% | -12.63M -92.13% | -4.34M -137.01% | -8.23M -- | -10.81M -- | -14.44M -14.40% | -1.88M +56.75% | -5.10M +38.11% | -8.50M +21.40% | -12.62M +12.66% | -2.43M -29.61% | -4.63M +9.26% | -7.15M +15.81% | -10.17M +19.36% | -2.55M -4.77% | -4.22M +8.76% | -5.98M +16.38% | -7.63M +24.96% | -3.96M +6.23% | -7.88M -3.22% | -4.88M -23.22% | -9.83M -24.72% | -9.83M -- |
Net Income Attributable to Minority Interests | -267.56K -- | -136.00K +49.17% | -53.00K -- | -94.00K +30.88% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income Attributable to Owners of the Company | -4.80M -- | -8.26M -72.05% | -3.46M -- | -6.34M +23.23% | -1.72M -- | -2.96M +14.36% | -6.57M -3.66% | -1.83M -6.45% | -12.63M -92.13% | -4.34M -137.01% | -8.23M -- | -10.81M -- | -14.44M -14.40% | -1.88M +56.75% | -5.10M +38.11% | -8.50M +21.40% | -12.62M +12.66% | -2.43M -29.61% | -4.63M +9.26% | -7.15M +15.81% | -10.17M +19.36% | -2.55M -4.77% | -4.22M +8.76% | -5.98M +16.38% | -7.63M +24.96% | -3.96M +6.23% | -7.88M -3.22% | -4.88M -23.22% | -9.83M -24.72% | -9.83M -- |
Preferred Stock Dividends | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 715.00K -- | 715.00K -- | 715.00K -- | 715.00K -- | -- -- | -- -- | -- -- | 2.59M +262.24% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income Attributable to Common Stockholders | -4.80M -- | -8.26M -72.05% | -3.46M -- | -6.34M +23.23% | -1.72M -- | -2.96M +14.36% | -6.57M -3.66% | -1.83M -6.45% | -12.63M -92.13% | -5.06M -176.04% | -8.95M -- | -11.53M -- | -15.16M -20.06% | -1.88M +62.86% | -5.10M +43.05% | -8.50M +26.27% | -15.21M -0.31% | -2.43M -29.61% | -4.63M +9.26% | -7.15M +15.81% | -10.17M +33.09% | -2.55M -4.77% | -4.22M +8.76% | -5.98M +16.38% | -7.63M +24.96% | -3.96M +6.23% | -7.88M -3.22% | -4.88M -23.22% | -9.83M -24.72% | -9.83M -- |
Other Comprehensive Income | -98.92K -- | 119.00K +220.29% | 420.00K -- | 636.00K +434.45% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -5.17M -- | -8.27M -60.18% | -3.10M -- | -5.80M +29.94% | -- -- | -2.96M +4.20% | -6.57M -13.35% | -- -- | -12.63M -92.13% | -- -- | -8.23M -- | -10.81M -- | -15.16M -20.06% | -- -- | -5.10M +38.11% | -8.50M +21.40% | -12.62M +16.78% | -- -- | -- -- | -- -- | -10.17M +19.36% | -- -- | -4.22M -- | -- -- | -- -- | -3.96M +6.23% | -- -- | -4.88M -23.22% | -- -- | -- -- |
Total Comprehensive Income Attributable to Minority Interests | -267.56K -- | -136.00K +49.17% | -53.00K -- | -94.00K +30.88% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -4.90M -- | -8.14M -66.15% | -3.04M -- | -5.70M +29.92% | -- -- | -2.96M +2.53% | -6.57M -15.22% | -- -- | -12.63M -92.13% | -- -- | -8.23M -- | -10.81M -- | -15.16M -20.06% | -- -- | -5.10M +38.11% | -8.50M +21.40% | -15.21M -0.31% | -- -- | -- -- | -- -- | -10.17M +33.09% | -- -- | -4.22M -- | -- -- | -- -- | -3.96M +6.23% | -- -- | -4.88M -23.22% | -- -- | -- -- |
Basic EPS | -0.21 -- | -0.3 -42.86% | -0.1 -- | -0.19 +36.67% | -0.05 -- | -0.08 +20.00% | -0.17 +10.53% | -0.04 +20.00% | -0.14 +17.65% | -0.03 +25.00% | -0.04 -- | -0.04 -- | -0.04 +71.43% | 0 +100.00% | -0.01 +75.00% | -0.02 +50.00% | -0.03 +25.00% | 0 -- | 0 +100.00% | -0.01 +50.00% | -0.01 +66.67% | 0 -- | 0 -- | 0 +100.00% | -17.92 -179100.00% | 0 -- | -10.86 +39.40% | 0 -- | -5.97 +45.03% | -5.97 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.14 -- | -- -- | -- -- | -- -- | -0.04 +71.43% | -- -- | -- -- | -- -- | -0.03 +25.00% | -- -- | -- -- | -- -- | -0.01 +66.67% | -- -- | 0 -- | -- -- | -17.92 -179100.00% | 0 -- | -10.86 +39.40% | 0 -- | -5.97 +45.03% | -5.97 -- |
Diluted EPS | -0.21 -- | -0.3 -42.86% | -0.1 -- | -0.19 +36.67% | -0.05 -- | -0.08 +20.00% | -0.17 +10.53% | -0.04 +20.00% | -0.14 +17.65% | -0.03 +25.00% | -0.04 -- | -0.04 -- | -0.04 +71.43% | 0 +100.00% | -0.01 +75.00% | -0.02 +50.00% | -0.03 +25.00% | 0 -- | 0 +100.00% | -0.01 +50.00% | -0.01 +66.67% | 0 -- | 0 -- | 0 +100.00% | -17.92 -179100.00% | 0 -- | -10.86 +39.40% | 0 -- | -5.97 +45.03% | -5.97 -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.14 -- | -- -- | -- -- | -- -- | -0.04 +71.43% | -- -- | -- -- | -- -- | -0.03 +25.00% | -- -- | -- -- | -- -- | -0.01 +66.67% | -- -- | 0 -- | -- -- | -17.92 -179100.00% | 0 -- | -10.86 +39.40% | 0 -- | -5.97 +45.03% | -5.97 -- |
You can ask Aime
What is Can-fite Biopharma's latest dividend and current dividend yield?What were the key takeaways from Can-fite Biopharma’s earnings call?What is Can-fite Biopharma's gross profit margin?Did Can-fite Biopharma beat or miss consensus estimates last quarter?What does Can-fite Biopharma do and what are its main business segments?What is the market's earnings forecast for Can-fite Biopharma next quarter?What factors drove the changes in Can-fite Biopharma's revenue and profit?What were the key takeaways from Can-fite Biopharma's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
